The treatment for Acute Lymphoblastic Leukemia (ALL) is a prolonged and intensive process, demanding substantial patience and commitment from patients, their families, and the medical team. The primary objective of this treatment is to reduce the percentage of leukemia cells (blasts) in the bone marrow from over 20% at diagnosis to below 5%. A subsequent critical goal is to eliminate the microscopic tumor burden, referred to as "minimal residual disease" (MRD). To achieve these specific treatment objectives in ALL, the following comprehensive approach is typically followed: